{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:12:29Z","timestamp":1777997549396,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Purpose<\/jats:title>\n                <jats:p>Little is known about long-term clinical outcomes or urate-lowering (ULT)\u00a0therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective analysis of gout patients who discontinued pegloticase using the Rheumatology Informatics System for Effectiveness (RISE) registry from 1\/2016 to 6\/2022. We defined discontinuation as a gap\u2009\u2265\u200912 weeks after last infusion. We examined outcomes beginning two weeks after last dose and identified ULT therapy following pegloticase discontinuation. We evaluated changes in lab values (SU, eGFR, CRP and ESR), comparing on- treatment (\u2264\u200915 days of the second pegloticase dose) to post-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 375 gout patients discontinuing pegloticase, median (IQR) laboratory changes following discontinuation were: SU: +2.4\u00a0mg\/dL (0.0,6.3); eGFR: -1.9 mL\/min (\u2212\u20098.7,3.7); CRP: -0.8\u00a0mg\/L (-12.8,0.0); and ESR: -4.0\u00a0mm\/hr (-13.0,0.0). Therapy post-discontinuation included oral ULTs (86.0%), restarting pegloticase (4.5%), and no documentation of ULT (9.5%), excluding patients with multiple same-day prescriptions (<jats:italic>n<\/jats:italic>\u2009=\u200917). Oral ULTs following pegloticase were: 62.7% allopurinol, 34.1% febuxostat. The median (IQR) time to starting\/restarting ULT was 92.0 days (55.0,173.0). Following ULT prescribing (\u2265\u200930 days), only 51.0% of patients had SU\u2009&lt;\u20096\u00a0mg\/dL. Patients restarting pegloticase achieved a median SU of 0.9\u00a0mg\/dL (IQR:0.2,9.7) and 58.3% had an SU\u2009&lt;\u20096\u00a0mg\/dL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pegloticase treats uncontrolled gout in patients with failed response to xanthine oxidase inhibitors, but among patients who discontinue, optimal treatment is unclear. Based on this analysis, only half of those starting another ULT achieved target SU. Close follow-up is needed to optimize outcomes after pegloticase discontinuation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-024-03318-5","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T09:02:14Z","timestamp":1712912534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation"],"prefix":"10.1186","volume":"26","author":[{"given":"Emily E.","family":"Holladay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Mudano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"6","key":"3318_CR1","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3318_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-021-05930-1","volume":"41","author":"TL Jansen","year":"2022","unstructured":"Jansen TL, Tanja G, Matthijs J. A historical journey of searching for uricosuric drugs. Clin Rheumatol. 2022;41(1):297\u2013305.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"3318_CR3","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/acr.25009","volume":"75","author":"N Hammam","year":"2023","unstructured":"Hammam N, Li J, Kay J, Izadi Z, Yazdany J, Schmajuk G. Monitoring and achievement of target serum urate among gout patients receiving long-term urate\u2010lowering therapy in the American College of Rheumatology RISE Registry. Arthritis Care Res (Hoboken). 2023;75(7):1544\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"3318_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/2042098617727714","volume":"8","author":"A Guttmann","year":"2017","unstructured":"Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations. Ther Adv Drug Saf. 2017;8(12):379\u201388.","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"3318_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/art.42335","volume":"75","author":"JK Botson","year":"2023","unstructured":"Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 2023;75(2):293\u2013304.","journal-title":"Arthritis Rheumatol"},{"key":"3318_CR6","unstructured":"Horizon Pharma PLC. KRYSTEXXA\u00ae (pegloticase) [package insert]. 2022."},{"issue":"11","key":"3318_CR7","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1002\/art.23993","volume":"58","author":"HSB Baraf","year":"2008","unstructured":"Baraf HSB, Matsumoto AK, Maroli AN, Waltrip RW. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum. 2008;58(11):3632\u20134.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3318_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321\u20135.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3318_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/art.41731","volume":"73","author":"PP Khanna","year":"2021","unstructured":"Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo\u2010controlled trial. Arthritis Rheumatol. 2021;73(8):1523\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"3318_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3899\/jrheum.200460","volume":"48","author":"JK Botson","year":"2021","unstructured":"Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, et al. Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR). J Rheumatol. 2021;48(5):767\u201374.","journal-title":"J Rheumatol"},{"issue":"7","key":"3318_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HSB, Huang W, Maroli AN, Waltrip RW, Hamburger SA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711\u201320.","journal-title":"JAMA"},{"issue":"2","key":"3318_CR12","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","volume":"16","author":"PE Lipsky","year":"2014","unstructured":"Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16(2):R60.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3318_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/MJT.0b013e318250f83d","volume":"21","author":"AA Abdellatif","year":"2014","unstructured":"Abdellatif AA, Elkhalili N. Management of gouty arthritis in patients with chronic kidney disease. Am J Ther. 2014;21(6):523\u201334.","journal-title":"Am J Ther"},{"issue":"2","key":"3318_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semarthrit.2012.03.013","volume":"42","author":"RVMD Curiel","year":"2012","unstructured":"Curiel RVMD, Guzman NJMD. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum. 2012;42(2):166\u201378.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3318_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90.","journal-title":"Arthritis Res Ther"},{"key":"3318_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fmed.2020.00166","volume":"7","author":"F Oliviero","year":"2020","unstructured":"Oliviero F, Bindoli S, Scanu A, Feist E, Doria A, Galozzi P, et al. Autoinflammatory mechanisms in crystal-induced arthritis. Front Med (Lausanne). 2020;7:166.","journal-title":"Front Med (Lausanne)"},{"key":"3318_CR17","doi-asserted-by":"crossref","unstructured":"Dalbeth NP, Merriman TRP, Stamp LKP. Gout. The Lancet (British edition). 2016;388(10055):2039-52.","DOI":"10.1016\/S0140-6736(16)00346-9"},{"key":"3318_CR18","unstructured":"American College of Rheumatology. About RISE Registry n.d. https:\/\/rheumatology.org\/about-rise-registry."},{"issue":"5","key":"3318_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/ki.2010.462","volume":"79","author":"LA Stevens","year":"2011","unstructured":"Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 2011;79(5):555\u201362.","journal-title":"Kidney Int"},{"issue":"2","key":"3318_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, Padnick-Silver L, LaMoreaux B, Albert JA, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"3318_CR21","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","volume":"50","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3):S31\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"3318_CR22","unstructured":"Yun H, LaMoreaux B, Chen L, Ledbetter S, Francis-Sedlack M, Saag K et al. Effectiveness and safety of pegloticase with concomitant immunomodulatory therapy [abstract]. Arthritis Rheumatol. 2021;73."},{"issue":"Suppl 2","key":"3318_CR23","first-page":"1360","volume":"76","author":"H Baraf","year":"2017","unstructured":"Baraf H, Morton A, LaMoreaux B, Kent J. AB0867\u2005pegloticase re-treatment after a gap in therapy: data from two phase iii trials and an open-label extension study. Ann Rheum Dis. 2017;76(Suppl 2):1360.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3318_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40744-018-0111-9","volume":"5","author":"AH Morton","year":"2018","unstructured":"Morton AH, Hosey T, LaMoreaux B. Retreatment with pegloticase after a gap in therapy in patients with gout: a report of four cases. Rheumatol Ther. 2018;5(2):583\u201394.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"3318_CR25","first-page":"1853","volume":"82","author":"O Troum","year":"2023","unstructured":"Troum O, Botson J, Obermeyer K, Verma S, Lamoreaux B. AB1255\u2005pegloticase\u2009+\u2009methotrexate cotherapy in uncontrolled gout patients with prior pegloticase monotherapy failure: findings of the advance open-label trial [abstract]. Ann Rheum Dis. 2023;82(Suppl 1):1853.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3318_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-0500-7-54","volume":"7","author":"RA Yood","year":"2014","unstructured":"Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Res Notes. 2014;7(1):54.","journal-title":"BMC Res Notes"},{"issue":"Suppl 1","key":"3318_CR27","first-page":"1646","volume":"81","author":"J Albert","year":"2022","unstructured":"Albert J, Broadwell A, Masri K, Padnick-Silver L, Lamoreaux B. AB1048\u2005estimated glomerular filtration rate changes in uncontrolled gout patients co-treated with pegloticase and methotrexate: a retrospective case series. Ann Rheum Dis. 2022;81(Suppl 1):1646.","journal-title":"Ann Rheum Dis"},{"key":"3318_CR28","unstructured":"Albert J, Broadwell AJ, Padnick-Silver L, Marder B, LaMoreaux B. eGFR changes in uncontrolled gout patients undergoing pegloticase\u2009+\u2009methotrexate co-therapy [abstract]. Arthritis Rheumatol. 2022;74."},{"issue":"12","key":"3318_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1759720X18807117","volume":"10","author":"K Ramsubeik","year":"2018","unstructured":"Ramsubeik K, Ramrattan LA, Kaeley GS, Singh JA. Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Therapeutic Adv Musculoskelet Disease. 2018;10(12):235\u201352.","journal-title":"Therapeutic Adv Musculoskelet Disease"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03318-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T08:16:52Z","timestamp":1714119412000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03318-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3318"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03318-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the University of Alabama at Birmingham Institutional Review Board (Birmingham, AL). This study was classified as exempt, waiving the requirement of informed consent. All study conduct adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EEH, ASM, FX, and JZ declare no conflicts of interest. TRM receives support from Elsevier, UpToDate, Horizon (now Amgen Inc.), Pfizer, Sanofi, UCB, and the Rheumatology Research Foundation. BL and LPS are employees of and stockholders in Horizon Therapeutics (now Amgen Inc.). JRC receives support for unrelated work from AbbVie, Amgen, Aqtual, Bendcare, BMS, CorEvitas, FASTER, GSK, Janssen, Lilly, Moderna, Novartis, Pfizer, Sanofi, Scipher, Setpoint, TNacity Blue Ocean, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}